Migraine vs Epilepsy — Clinical Trial Comparison
Migraine
Severe recurrent headache disorder with neurological symptoms
VS
Epilepsy
Neurological condition causing recurrent seizures
Migraine and epilepsy are two of the most prevalent neurological conditions in the UK, sharing intriguing overlaps — both involve cortical spreading depression and some medications work for both. However, their trial landscapes differ. Migraine trials have been revolutionised by CGRP-targeting therapies, while epilepsy trials focus on better seizure control, novel mechanisms, and devices for drug-resistant cases.
Key Differences at a Glance
| Feature | Migraine | Epilepsy |
|---|---|---|
| Primary symptoms | Severe headache, nausea, photophobia, aura (in 30%) | Seizures (various types), loss of awareness, convulsions, post-ictal confusion |
| Common subtypes | Episodic, chronic, with/without aura, vestibular, menstrual, hemiplegic | Focal, generalised, absence, tonic-clonic, myoclonic, drug-resistant |
| Severity scoring | MIDAS, HIT-6, migraine days/month | Seizure frequency, seizure type, EEG findings, drug resistance classification |
| Shared mechanisms | Cortical spreading depression, neurotransmitter imbalance | Cortical spreading depression (some seizure types), neurotransmitter imbalance |
| NICE first-line | Triptans (acute), topiramate/propranolol (prophylactic), CGRP mAbs | Lamotrigine, levetiracetam, sodium valproate (type-dependent) |
| Prevalence in UK | ~10 million (1 in 6 adults) | ~600,000 (1 in 100) |
Clinical Trial Availability
| Trial Aspect | Migraine | Epilepsy |
|---|---|---|
| UK trials actively recruiting | 30-50 studies | 40-60 studies |
| Most common trial phase | Phase 2-3 | Phase 2-3 |
| Top interventions tested | CGRP inhibitors, ditans, gepants, neuromodulation, behavioural | Novel ASMs, gene therapy, neuromodulation, cannabidiol, surgical approaches |
| Prevention trials | Major focus (CGRP mAbs, oral CGRP antagonists) | Active (new ASMs, epilepsy surgery outcomes, neurostimulation) |
| Device trials | Active (Cefaly, sTMS, gammaCore) | Active (VNS, RNS, DBS, responsive neurostimulation) |
| Digital/remote trials | App-based tracking, telemedicine | Wearable seizure detection, digital diaries |
Exciting Emerging Treatments
Migraine Trials
- Oral CGRP receptor antagonists (gepants) — atogepant, rimegepant for prevention
- Anti-PACAP therapies — new target beyond CGRP for migraine prevention
- Ditans (lasmiditan) — serotonin receptor agonist without vasoconstriction
- Neuromodulation devices — non-invasive vagus nerve stimulation, external TMS
- Anti-CGRP peptides — longer-acting, potentially fewer side effects
- Behavioural intervention trials — CBT, biofeedback, mindfulness with digital delivery
Epilepsy Trials
- Novel antiseizure medications — compounds with new mechanisms (SV2A modulators, KCNQ openers)
- Cannabidiol (CBD) — Epidiolex and beyond for drug-resistant epilepsy
- Gene therapy — targeting specific genetic epilepsies (SCN1A, KCNQ2)
- Fenfluramine — repurposed drug for Dravet syndrome and Lennox-Gastaut
- Responsive neurostimulation (RNS) — detecting and stopping seizures in real-time
- Artificial intelligence — seizure prediction algorithms and automated detection
💡 Not sure which trials you qualify for?
Use our Smart Matcher to answer a few questions about your condition and we'll find the most relevant trials for your specific situation — free, instant results.
Eligibility Differences
Migraine Trial Criteria
- Confirmed migraine diagnosis (ICHD-3 criteria) with minimum frequency (typically 4+ days/month)
- Chronic migraine trials: 15+ headache days/month with 8+ migraine days
- Failed or intolerant to 2-3 preventive medications for preventive trials
- Medication overuse must be addressed before enrolling in most trials
- CGRP trials: no prior CGRP therapy for some studies (treatment-naive cohort)
Epilepsy Trial Criteria
- Confirmed epilepsy diagnosis with documented seizure types
- Drug-resistant epilepsy trials: failed 2+ appropriate ASMs at adequate doses
- Seizure frequency documented over baseline period (typically 4+ seizures/month)
- EEG and MRI findings often required to characterise seizure focus
- Genetic epilepsy trials: confirmed pathogenic variant in specific gene
Frequently Asked Questions
Can I join a clinical trial if I have both Migraine and Epilepsy?
It depends on the specific trial. Many trials allow comorbid conditions as long as the primary condition being studied is clearly dominant. Some trials explicitly exclude patients with significant overlapping conditions. Always check the eligibility criteria carefully and discuss with both the trial team and your specialist.
Which condition has more clinical trials available in the UK?
Both Migraine and Epilepsy have robust research pipelines with new studies opening regularly. The number of trials varies over time as new studies launch and others complete. Check our condition pages for the most current trial availability.
What should I consider when choosing between trials for these conditions?
Consider which condition impacts your quality of life most, what treatments you've already tried, the trial phase (earlier phases are more experimental), the time commitment involved, and whether the trial offers access to treatments not otherwise available. Your specialist can help you prioritise.